Moderna Inc. Stock

Moderna's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management

On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most

Making predictions about how stocks will perform is easy. Predicting with any significant degree of accuracy, on the other hand, is extremely hard.

I think that's especially true with biotech stocks

Moderna Therapeutics (NASDAQ: MRNA) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine. While COVID

Moderna's (NASDAQ: MRNA) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand for its coronavirus vaccine waned, but seemed

September isn't known to be one of the best months for stock performance. Over the past century, the S&P 500 index has, on average, slipped during this month, a phenomenon known as the "September

"Buy when there's blood in the streets," was something famous banker Baron Rothschild once advised, suggesting the time to invest is when everyone else is fleeing a particular asset or the market in

Image source: The Motley Fool.

Moderna (NASDAQ: MRNA)Q2 2024 Earnings CallAug 01, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Moderna (NASDAQ: MRNA) went from being an unknown biotech to a household name thanks to its work developing and marketing one of the most successful COVID-19 vaccines. Though the company has

Moderna (NASDAQ: MRNA) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have

Some investors might view Moderna (NASDAQ: MRNA) as a shooting star that shined bright for a while then flamed out. In 2022, the biotech company generated sales of nearly $18.9 billion, but it

Although Moderna (NASDAQ: MRNA) is now a somewhat famous biotech, it was a relatively unknown, clinical-stage company just five years ago. Its success in the COVID-19 vaccine market catapulted it to

The shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna (NASDAQ: MRNA). Biotech stocks generally rise after a product they spent years developing earns

Moderna (NASDAQ: MRNA) jumped into the limelight when it started developing a coronavirus vaccine candidate. And the stock soared as the vaccine raced across the finish line and went on to bring in

Shares of Moderna (NASDAQ: MRNA) were sinking 9% lower this week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The decline appears to be the result of

The past two-and-a-half years have been rough for Moderna (NASDAQ: MRNA). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche to shrink

Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday

Moderna (NASDAQ: MRNA) isn't new to artificial intelligence (AI). The biotech best known for its billion-dollar coronavirus vaccine has been using this hot technology for years to help it save

Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) both entered the coronavirus vaccine race around the same time, in early pandemic days, and their shares soared -- in fact, Novavax rose the most

Investors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that

Equities have been on a bull run for well over a year. Though it might be tempting to invest in stocks that have largely been in tandem with the broader market, it's even better to consider those

Moderna (NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every level of the biotech's operations, and the implications could perhaps be significant for investors

Five years ago, pharmaceutical company Moderna (NASDAQ: MRNA) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of

Moderna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells the Spikevax COVID-19 vaccine, saw its share

Image source: The Motley Fool.

Moderna (NASDAQ: MRNA)Q1 2024 Earnings CallMay 02, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com